Literature DB >> 33817230

Effect of FibroScan test in antiviral therapy for HBV-infected patients with ALT <2 upper limit of normal.

Xian-Zhi Han1, Shu-Feng Zhang1, Jia-Yin Yi1, Bin Wang1, Hui-Qing Sun1.   

Abstract

OBJECTIVE: The objective of this study is to detect the liver stiffness of hepatitis B virus (HBV)-infected patients with an alanine aminotransferase (ALT) level of <2 upper limit of normal (2ULN) by FibroScan and compare histological changes to assess the progression of liver lesions and its test results.
METHODS: There were 36 patients who had a liver FibroScan degree of >7.3 KD (F1), and a liver biopsy was conducted. Along with serology of liver fibrosis, indexes and hierarchical processing were used for evaluation. The correlation between these factors was analyzed.
RESULTS: The histopathological results of the liver were closely correlated with liver hardness. In the pathological diagnosis of chronic hepatitis, G represents the grade of inflammation and S represents the stage of hepatic fibrosis. Pathological examination results of H&E staining of liver tissue sections revealed that the area under the work characteristic curve of the subjects in G2S1, G2S2, G3S2, and G3S3 stages was 0.923, 0.916, 0.955, and 0.971, respectively, with diagnostic cut-off values of 9.03, 9.85, 15.14, and 30.67, respectively. Furthermore, hydroxyapatite, type III procollagen, laminin, and type IV collagen of serum fibrosis indexes are associated with liver stiffness values (P < 0.05).
CONCLUSION: FibroScan can be used as an alternative to liver biopsy. It is meaningful in determining whether HBV infected patients with an ALT level of <2 ULN should receive antiviral therapy.
© 2020 Xian-Zhi Han et al., published by De Gruyter.

Entities:  

Keywords:  ALT <2 ULN; FibroScan; HBV infection; antiviral therapy opportunity

Year:  2020        PMID: 33817230      PMCID: PMC7874573          DOI: 10.1515/biol-2020-0044

Source DB:  PubMed          Journal:  Open Life Sci        ISSN: 2391-5412            Impact factor:   0.938


  17 in total

1.  Quantitative analysis of hepatic macro- and microvascular alterations during cirrhogenesis in the rat.

Authors:  Geert Peeters; Charlotte Debbaut; Adrian Friebel; Pieter Cornillie; Winnok H De Vos; Kasper Favere; Ingrid Vander Elst; Tim Vandecasteele; Tim Johann; Luc Van Hoorebeke; Diethard Monbaliu; Dirk Drasdo; Stefan Hoehme; Wim Laleman; Patrick Segers
Journal:  J Anat       Date:  2017-12-04       Impact factor: 2.610

2.  Ultrastructural characteristics of the respective forms of hepatic stellate cells in chronic hepatitis B as an example of high fibroblastic cell plasticity. The first assessment in children.

Authors:  Joanna Maria Lotowska; Maria Elzbieta Sobaniec-Lotowska; Dariusz Marek Lebensztejn
Journal:  Adv Med Sci       Date:  2017-11-06       Impact factor: 3.287

Review 3.  Hepatitis B virus infection.

Authors:  Man-Fung Yuen; Ding-Shinn Chen; Geoffrey M Dusheiko; Harry L A Janssen; Daryl T Y Lau; Stephen A Locarnini; Marion G Peters; Ching-Lung Lai
Journal:  Nat Rev Dis Primers       Date:  2018-06-07       Impact factor: 52.329

4.  Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial.

Authors:  Tassanee Sriprayoon; Chulabhorn Mahidol; Teerapat Ungtrakul; Pattra Chun-On; Kamonwan Soonklang; Wanvisa Pongpun; Charlie Laohapand; Jiraporn Dechma; Charinthip Pothijaroen; Chirayu Auewarakul; Tawesak Tanwandee
Journal:  Hepatol Res       Date:  2016-06-08       Impact factor: 4.288

5.  Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy.

Authors:  Qiang Li; Liang Chen; Yu Zhou
Journal:  Clin Exp Med       Date:  2018-01-19       Impact factor: 3.984

6.  Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.

Authors:  Young Eun Chon; Jun Yong Park; Sung-Min Myoung; Kyu Sik Jung; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

7.  Noninvasive evaluation of liver fibrosis using real-time tissue elastography and transient elastography (FibroScan).

Authors:  Fankun Meng; Ying Zheng; Qi Zhang; Xiaojie Mu; Xiaoluan Xu; Haiying Zhang; Lei Ding
Journal:  J Ultrasound Med       Date:  2015-03       Impact factor: 2.153

8.  Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B.

Authors:  Mauro Viganò; Sara Massironi; Pietro Lampertico; Massimo Iavarone; Silvia Paggi; Roberta Pozzi; Dario Conte; Massimo Colombo
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-02       Impact factor: 2.566

9.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

10.  Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment.

Authors:  Sheng-Di Wu; Li-Li Liu; Ji-Lin Cheng; Yun Liu; Li-Sha Cheng; Si-Qi Wang; Wei Ma; Li-Ping Chen; Yu-Jen Tseng; Ji-Yao Wang; Xi-Zhong Shen; Wei Jiang
Journal:  Clin Exp Med       Date:  2018-04-25       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.